This postdoctoral fellowship program in clinical pharmacology provides training in basic and applied human pharmacology for those committed to careers integrating basic and translational research and patient care. The objective of this program is to provide training across the continuum spanning mechanistic, translational, and clinical investigation, with an emphasis on pharmacology and experimental therapeutics, to replenish the dwindling national supply of clinician-investigators. The majority of fellows'time is focused on independent, hypothesis-driven research. The breadth of clinical pharmacology is delivered using a curriculum built upon the institutional NIH K30 Training Program in Human Investigation, including courses in basic and clinical pharmacology, study design, statistics, epidemiology, and ethics, as well as conferences including journal club, ethics, and research seminars. Experiential rotations include the editorial board of the Annals of Internal Medicine, pharmaceutical drug development at Merck Research Laboratories, and human clinical trials in the Jefferson Clinical Research Unit. Trainees customize their education by choosing a range of electives congruent with their career aspirations. These include Institutional Review Board membership, adult PK/PD modeling at Merck, pediatric pharmacometrics at Children's Hospital of Philadelphia, or rotations at the Food and Drug Administration (FDA). Research opportunities are offered by 39 preceptors, representing 10 departments and 3 divisions within the Department of Medicine. These preceptors represent a broad spectrum of disciplines, approaches, and methodologies to ensure a wide selection of training opportunities. Preceptors are selected on the basis of their productive research programs in basic or translational pharmacology funded through extramural mechanisms, success in training competitive investigators, and commitment and ability to train postdoctoral fellows. Programs of these preceptors constitute 13 general areas that span drug discovery, development, utilization, and regulation. Trainees selected from candidates with M.D., Ph.D., or Pharm.D. degrees in areas related to discipline-specific objectives, spend a minimum of 2 years developing core expertise in clinical pharmacology. The program has an established track record of recruiting and retaining highly qualified, diverse trainees who have been uniformly successful in obtaining, and advancing in, academic appointments in clinical pharmacology, leadership positions in the pharmaceutical industry, and regulatory and policy positions as scientists at the FDA.

Public Health Relevance

Advances in the new biology are transforming drug therapy, the most cost-effective component of healthcare. Yet, at this time of scientific opportunity, shortages in specialized workforces limit the discovery and development of drugs and their safe use. To fill that gap, the Jefferson Clinical Pharmacology Fellowship Program is training clinician scientists to translate new discoveries into drugs that revolutionize patient care.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
5T32GM008562-19
Application #
8500325
Study Section
Special Emphasis Panel (ZGM1-BRT-5 (PD))
Program Officer
Okita, Richard T
Project Start
1995-07-01
Project End
2015-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
19
Fiscal Year
2013
Total Cost
$288,130
Indirect Cost
$20,010
Name
Thomas Jefferson University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Kim, G W; Lin, J E; Blomain, E S et al. (2014) Antiobesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ther 95:53-66
Rodriguez, Elena; Barthold, Julia S; Kreiger, Portia A et al. (2014) The orl rat is more responsive to methacholine challenge than wild type. Pulm Pharmacol Ther 29:199-208
Wilson, Chantell; Lin, Jieru E; Li, Peng et al. (2014) The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer. Cancer Epidemiol Biomarkers Prev 23:2328-37
Witek, Matthew E; Snook, Adam E; Lin, Jieru E et al. (2014) A novel CDX2 isoform regulates alternative splicing. PLoS One 9:e104293
de Jongh, B E; Locke, R; Mackley, A et al. (2014) Work of breathing indices in infants with respiratory insufficiency receiving high-flow nasal cannula and nasal continuous positive airway pressure. J Perinatol 34:27-32
Levenbrown, Yosef; Penfil, Scott; Rodriguez, Elena et al. (2013) Use of insulin to decrease septic shock-induced myocardial depression in a porcine model. Inflammation 36:1494-502
Martinez Cantarin, Maria P; Waldman, Scott A; Doria, Cataldo et al. (2013) The adipose tissue production of adiponectin is increased in end-stage renal disease. Kidney Int 83:487-94
Blomain, Erik S; Lin, Jieru E; Kraft, Crystal L et al. (2013) Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis. Expert Rev Clin Pharmacol 6:557-64
Gibbons, Ahmara V; Lin, Jieru E; Kim, Gilbert W et al. (2013) Intestinal GUCY2C prevents TGF-* secretion coordinating desmoplasia and hyperproliferation in colorectal cancer. Cancer Res 73:6654-66
Kim, Gilbert W; Lin, Jieru E; Blomain, Erik S et al. (2013) New advances in models and strategies for developing anti-obesity drugs. Expert Opin Drug Discov 8:655-71

Showing the most recent 10 out of 39 publications